Cargando…

Model‐based dose selection to inform translational clinical oncology development of WNT974, a first‐in‐class Porcupine inhibitor

WNT974 is a potent, selective, and orally bioavailable first‐in‐class inhibitor of Porcupine, a membrane‐bound O‐acyltransferase required for Wnt secretion, currently under clinical development in oncology. A phase I clinical trial is being conducted in patients with advanced solid tumors. During th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yan, Huang, Pai‐Hsi, Woolfenden, Steve, Myers, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283749/
https://www.ncbi.nlm.nih.gov/pubmed/35620969
http://dx.doi.org/10.1111/cts.13287